Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
Attain Performa(TM) Quadripolar Lead Study
The purpose of the study is to evaluate the safety and efficacy of the Medtronic Attain Performa Quadripolar Leads (Model 4298, 4398, and 4598) during and post the implant procedure. This study will also assess the interactions of the Attain Performa leads with the entire Medtronic CRT-D system.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Device: Attain Performa Pacing Lead (along with a standard CRT-D system)
Eligibility
Inclusion Criteria:
- Patient is indicated for implant of a CRT-D device and left-heart lead per local
indications (In US only this is based on Class I and II indications for CRT-D implant
per HRS/ACC/AHA guidelines)
- Patient (or legally authorized representative) has signed and dated the study-specific
Consent Form
- Patient is 18 years of age or older, or is of legal age to give informed consent per
local and national law
- Patient is expected to remain available for follow-up visits
- Patient understands the study and agrees to comply with study protocol
Exclusion Criteria:
- Patient has a previous LV lead implanted or previous implant attempt within 30 days of
enrollment or has ongoing AEs from a previous unsuccessful implant attempt
- Patient has contraindications for standard transvenous cardiac pacing (e.g.,
mechanical right heart valve)
- Patient has had a heart transplant (Note: Patients waiting for heart transplants are
allowed in the study)
- Patient is contraindicated for < 1 mg dexamethasone acetate
- Patient is currently enrolled or planning to participate in a potentially confounding
drug or device study during the course of this study. (Note: Co-enrollment in
concurrent studies may be allowed provided that documented pre-approval is obtained
from Medtronic's study manager)
- Patient has a life expectancy less than 180 days
- Patient with exclusion criteria required by local law (e.g. age, pregnancy, breast
feeding, etc.)
- In US, women of childbearing potential must have a negative pregnancy test 7 days
prior to implant to be included
- Patient is unable to tolerate an urgent thoracotomy
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Linda Norton, RN, MSN
(650) 725-5597
I'm interested
Psoriasis Clinical Trials
Attain Performa(TM) Quadripolar Lead Study
The purpose of the study is to evaluate the safety and efficacy of the Medtronic Attain Performa Quadripolar Leads (Model 4298, 4398, and 4598) during and post the implant procedure. This study will also assess the interactions of the Attain Performa leads with the entire Medtronic CRT-D system.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Device: Attain Performa Pacing Lead (along with a standard CRT-D system)
Eligibility
Inclusion Criteria:
- Patient is indicated for implant of a CRT-D device and left-heart lead per local
indications (In US only this is based on Class I and II indications for CRT-D implant
per HRS/ACC/AHA guidelines)
- Patient (or legally authorized representative) has signed and dated the study-specific
Consent Form
- Patient is 18 years of age or older, or is of legal age to give informed consent per
local and national law
- Patient is expected to remain available for follow-up visits
- Patient understands the study and agrees to comply with study protocol
Exclusion Criteria:
- Patient has a previous LV lead implanted or previous implant attempt within 30 days of
enrollment or has ongoing AEs from a previous unsuccessful implant attempt
- Patient has contraindications for standard transvenous cardiac pacing (e.g.,
mechanical right heart valve)
- Patient has had a heart transplant (Note: Patients waiting for heart transplants are
allowed in the study)
- Patient is contraindicated for < 1 mg dexamethasone acetate
- Patient is currently enrolled or planning to participate in a potentially confounding
drug or device study during the course of this study. (Note: Co-enrollment in
concurrent studies may be allowed provided that documented pre-approval is obtained
from Medtronic's study manager)
- Patient has a life expectancy less than 180 days
- Patient with exclusion criteria required by local law (e.g. age, pregnancy, breast
feeding, etc.)
- In US, women of childbearing potential must have a negative pregnancy test 7 days
prior to implant to be included
- Patient is unable to tolerate an urgent thoracotomy
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Linda Norton, RN, MSN
(650) 725-5597
I'm interested
Dermatology Clinical Trials
Attain Performa(TM) Quadripolar Lead Study
The purpose of the study is to evaluate the safety and efficacy of the Medtronic Attain Performa Quadripolar Leads (Model 4298, 4398, and 4598) during and post the implant procedure. This study will also assess the interactions of the Attain Performa leads with the entire Medtronic CRT-D system.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Device: Attain Performa Pacing Lead (along with a standard CRT-D system)
Eligibility
Inclusion Criteria:
- Patient is indicated for implant of a CRT-D device and left-heart lead per local
indications (In US only this is based on Class I and II indications for CRT-D implant
per HRS/ACC/AHA guidelines)
- Patient (or legally authorized representative) has signed and dated the study-specific
Consent Form
- Patient is 18 years of age or older, or is of legal age to give informed consent per
local and national law
- Patient is expected to remain available for follow-up visits
- Patient understands the study and agrees to comply with study protocol
Exclusion Criteria:
- Patient has a previous LV lead implanted or previous implant attempt within 30 days of
enrollment or has ongoing AEs from a previous unsuccessful implant attempt
- Patient has contraindications for standard transvenous cardiac pacing (e.g.,
mechanical right heart valve)
- Patient has had a heart transplant (Note: Patients waiting for heart transplants are
allowed in the study)
- Patient is contraindicated for < 1 mg dexamethasone acetate
- Patient is currently enrolled or planning to participate in a potentially confounding
drug or device study during the course of this study. (Note: Co-enrollment in
concurrent studies may be allowed provided that documented pre-approval is obtained
from Medtronic's study manager)
- Patient has a life expectancy less than 180 days
- Patient with exclusion criteria required by local law (e.g. age, pregnancy, breast
feeding, etc.)
- In US, women of childbearing potential must have a negative pregnancy test 7 days
prior to implant to be included
- Patient is unable to tolerate an urgent thoracotomy
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Linda Norton, RN, MSN
(650) 725-5597
I'm interested
Pediatric Dermatology Clinical Trials
Attain Performa(TM) Quadripolar Lead Study
The purpose of the study is to evaluate the safety and efficacy of the Medtronic Attain Performa Quadripolar Leads (Model 4298, 4398, and 4598) during and post the implant procedure. This study will also assess the interactions of the Attain Performa leads with the entire Medtronic CRT-D system.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Device: Attain Performa Pacing Lead (along with a standard CRT-D system)
Eligibility
Inclusion Criteria:
- Patient is indicated for implant of a CRT-D device and left-heart lead per local
indications (In US only this is based on Class I and II indications for CRT-D implant
per HRS/ACC/AHA guidelines)
- Patient (or legally authorized representative) has signed and dated the study-specific
Consent Form
- Patient is 18 years of age or older, or is of legal age to give informed consent per
local and national law
- Patient is expected to remain available for follow-up visits
- Patient understands the study and agrees to comply with study protocol
Exclusion Criteria:
- Patient has a previous LV lead implanted or previous implant attempt within 30 days of
enrollment or has ongoing AEs from a previous unsuccessful implant attempt
- Patient has contraindications for standard transvenous cardiac pacing (e.g.,
mechanical right heart valve)
- Patient has had a heart transplant (Note: Patients waiting for heart transplants are
allowed in the study)
- Patient is contraindicated for < 1 mg dexamethasone acetate
- Patient is currently enrolled or planning to participate in a potentially confounding
drug or device study during the course of this study. (Note: Co-enrollment in
concurrent studies may be allowed provided that documented pre-approval is obtained
from Medtronic's study manager)
- Patient has a life expectancy less than 180 days
- Patient with exclusion criteria required by local law (e.g. age, pregnancy, breast
feeding, etc.)
- In US, women of childbearing potential must have a negative pregnancy test 7 days
prior to implant to be included
- Patient is unable to tolerate an urgent thoracotomy
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Linda Norton, RN, MSN
(650) 725-5597
I'm interested
Attain Performa(TM) Quadripolar Lead Study
The purpose of the study is to evaluate the safety and efficacy of the Medtronic Attain Performa Quadripolar Leads (Model 4298, 4398, and 4598) during and post the implant procedure. This study will also assess the interactions of the Attain Performa leads with the entire Medtronic CRT-D system.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Device: Attain Performa Pacing Lead (along with a standard CRT-D system)
Eligibility
Inclusion Criteria:
- Patient is indicated for implant of a CRT-D device and left-heart lead per local
indications (In US only this is based on Class I and II indications for CRT-D implant
per HRS/ACC/AHA guidelines)
- Patient (or legally authorized representative) has signed and dated the study-specific
Consent Form
- Patient is 18 years of age or older, or is of legal age to give informed consent per
local and national law
- Patient is expected to remain available for follow-up visits
- Patient understands the study and agrees to comply with study protocol
Exclusion Criteria:
- Patient has a previous LV lead implanted or previous implant attempt within 30 days of
enrollment or has ongoing AEs from a previous unsuccessful implant attempt
- Patient has contraindications for standard transvenous cardiac pacing (e.g.,
mechanical right heart valve)
- Patient has had a heart transplant (Note: Patients waiting for heart transplants are
allowed in the study)
- Patient is contraindicated for < 1 mg dexamethasone acetate
- Patient is currently enrolled or planning to participate in a potentially confounding
drug or device study during the course of this study. (Note: Co-enrollment in
concurrent studies may be allowed provided that documented pre-approval is obtained
from Medtronic's study manager)
- Patient has a life expectancy less than 180 days
- Patient with exclusion criteria required by local law (e.g. age, pregnancy, breast
feeding, etc.)
- In US, women of childbearing potential must have a negative pregnancy test 7 days
prior to implant to be included
- Patient is unable to tolerate an urgent thoracotomy
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Linda Norton, RN, MSN
(650) 725-5597
I'm interested
Attain Performa(TM) Quadripolar Lead Study
The purpose of the study is to evaluate the safety and efficacy of the Medtronic Attain Performa Quadripolar Leads (Model 4298, 4398, and 4598) during and post the implant procedure. This study will also assess the interactions of the Attain Performa leads with the entire Medtronic CRT-D system.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Device: Attain Performa Pacing Lead (along with a standard CRT-D system)
Eligibility
Inclusion Criteria:
- Patient is indicated for implant of a CRT-D device and left-heart lead per local
indications (In US only this is based on Class I and II indications for CRT-D implant
per HRS/ACC/AHA guidelines)
- Patient (or legally authorized representative) has signed and dated the study-specific
Consent Form
- Patient is 18 years of age or older, or is of legal age to give informed consent per
local and national law
- Patient is expected to remain available for follow-up visits
- Patient understands the study and agrees to comply with study protocol
Exclusion Criteria:
- Patient has a previous LV lead implanted or previous implant attempt within 30 days of
enrollment or has ongoing AEs from a previous unsuccessful implant attempt
- Patient has contraindications for standard transvenous cardiac pacing (e.g.,
mechanical right heart valve)
- Patient has had a heart transplant (Note: Patients waiting for heart transplants are
allowed in the study)
- Patient is contraindicated for < 1 mg dexamethasone acetate
- Patient is currently enrolled or planning to participate in a potentially confounding
drug or device study during the course of this study. (Note: Co-enrollment in
concurrent studies may be allowed provided that documented pre-approval is obtained
from Medtronic's study manager)
- Patient has a life expectancy less than 180 days
- Patient with exclusion criteria required by local law (e.g. age, pregnancy, breast
feeding, etc.)
- In US, women of childbearing potential must have a negative pregnancy test 7 days
prior to implant to be included
- Patient is unable to tolerate an urgent thoracotomy
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Linda Norton, RN, MSN
(650) 725-5597
I'm interested